DolPHIN-2 publishes trial primary outcome

01 Jun 2020

In May 2020, the primary outcome analysis from the DolPHIN-2 clinical trial was published in The Lancet HIV.

The study addresses an important knowledge gap around vertical transmission of HIV in women starting treatment late on in pregnancy.  Dolutegravir was found to reduce the viral load faster than efavirenz in pregnant women.  Although both medications were well tolerated by mothers and infants, more mothers who received dolutegravir developed serious adverse events (driven mainly by prolonged pregnancies) than did those who received efavirenz.

The data support the revision to WHO guidelines recommending the transition to dolutegravir in first-line ART for all adults, regardless of pregnancy or child-bearing potential.

You can access the paper here.